NCT00255047View on ClinicalTrials.gov

Safety and Immune Response of Different Pediatric Combination Vaccines.

PHASE3CompletedINTERVENTIONAL
Enrollment

2,167

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

July 31, 2008

Study Completion Date

February 28, 2009

Conditions
DiphtheriaPolioPertussis
Interventions
BIOLOGICAL

DAPTACEL®. (DTaP), IPOL®., and ActHIB®.

0.5 mL, Intramuscular

BIOLOGICAL

Pentacel®: DTaP-IPV/Hib combined

0.5 mL, Intramuscular

BIOLOGICAL

DTaP-IPV and ActHIB®

0.5 mL, Intramuscular

BIOLOGICAL

Pentacel®: DTaP-IPV/Hib combined

0.5 mL, Intramuscular

Trial Locations (36)

13088

Liverpool

15227

Pittsburgh

15241

Pittsburgh

19401

Norristown

21201

Baltimore

25701

Huntington

30062

Marietta

33410

Palm Beach Gardens

35401

Tuscaloosa

37660

Kingsport

40004

Bardstown

44514

Youngstown

45424

Huber Heights

68131

Omaha

71111

Bossier City

72205

Little Rock

72401

Jonesboro

72703

Fayetteville

76107

Fort Worth

78205

San Antonio

78229

San Antonio

79124

Amarillo

84095

South Jordan

84604

Provo

84790

St. George

90723

Paramount

94609

Oakland

94613

Oakland

94618

Oakland

98664

Vancouver

99216

Spokane

Unknown

Fountain Valley

Ithaca

Marshfield

06360

Norwich

01801

Woburn

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00255047 - Safety and Immune Response of Different Pediatric Combination Vaccines. | Biotech Hunter | Biotech Hunter